297 related articles for article (PubMed ID: 32019610)
1. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
Roberts M; Sevastou I; Imaizumi Y; Mistry K; Talma S; Dey M; Gartlon J; Ochiai H; Zhou Z; Akasofu S; Tokuhara N; Ogo M; Aoyama M; Aoyagi H; Strand K; Sajedi E; Agarwala KL; Spidel J; Albone E; Horie K; Staddon JM; de Silva R
Acta Neuropathol Commun; 2020 Feb; 8(1):13. PubMed ID: 32019610
[TBL] [Abstract][Full Text] [Related]
2. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
3. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms.
Hosokawa M; Masuda-Suzukake M; Shitara H; Shimozawa A; Suzuki G; Kondo H; Nonaka T; Campbell W; Arai T; Hasegawa M
Brain; 2022 Mar; 145(1):349-361. PubMed ID: 34515757
[TBL] [Abstract][Full Text] [Related]
5. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
6. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains.
Mukherjee S; Dubois C; Perez K; Varghese S; Birchall IE; Leckey M; Davydova N; McLean C; Nisbet RM; Roberts BR; Li QX; Masters CL; Streltsov VA
J Neurochem; 2023 Feb; 164(4):529-552. PubMed ID: 36271678
[TBL] [Abstract][Full Text] [Related]
8. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.
Dai CL; Chen X; Kazim SF; Liu F; Gong CX; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2015 Apr; 122(4):607-17. PubMed ID: 25233799
[TBL] [Abstract][Full Text] [Related]
9. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
[TBL] [Abstract][Full Text] [Related]
10. Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies.
Luk C; Giovannoni G; Williams DR; Lees AJ; de Silva R
J Neurosci Methods; 2009 May; 180(1):34-42. PubMed ID: 19427527
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.
Vandermeeren M; Borgers M; Van Kolen K; Theunis C; Vasconcelos B; Bottelbergs A; Wintmolders C; Daneels G; Willems R; Dockx K; Delbroek L; Marreiro A; Ver Donck L; Sousa C; Nanjunda R; Lacy E; Van De Casteele T; Van Dam D; De Deyn PP; Kemp JA; Malia TJ; Mercken MH
J Alzheimers Dis; 2018; 65(1):265-281. PubMed ID: 30040731
[TBL] [Abstract][Full Text] [Related]
12. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
13. Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease.
Kraus A; Saijo E; Metrick MA; Newell K; Sigurdson CJ; Zanusso G; Ghetti B; Caughey B
Acta Neuropathol; 2019 Apr; 137(4):585-598. PubMed ID: 30570675
[TBL] [Abstract][Full Text] [Related]
14. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
15. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.
Spencer B; Brüschweiler S; Sealey-Cardona M; Rockenstein E; Adame A; Florio J; Mante M; Trinh I; Rissman RA; Konrat R; Masliah E
Acta Neuropathol; 2018 Jul; 136(1):69-87. PubMed ID: 29934874
[TBL] [Abstract][Full Text] [Related]
16. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
17. Structural disorder in four-repeat Tau fibrils reveals a new mechanism for barriers to cross-seeding of Tau isoforms.
Weismiller HA; Murphy R; Wei G; Ma B; Nussinov R; Margittai M
J Biol Chem; 2018 Nov; 293(45):17336-17348. PubMed ID: 30242125
[TBL] [Abstract][Full Text] [Related]
18. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
Vander Zanden CM; Chi EY
J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
[TBL] [Abstract][Full Text] [Related]
19. Passive tau-based immunotherapy for tauopathies.
Panza F; Solfrizzi V; Daniele A; Lozupone M
Handb Clin Neurol; 2023; 196():611-619. PubMed ID: 37620094
[TBL] [Abstract][Full Text] [Related]
20. Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease.
Gibbons GS; Kim SJ; Wu Q; Riddle DM; Leight SN; Changolkar L; Xu H; Meymand ES; O'Reilly M; Zhang B; Brunden KR; Trojanowski JQ; Lee VMY
Mol Neurodegener; 2020 Nov; 15(1):64. PubMed ID: 33148293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
